CURRICULUM VITAE - sph.unc.edu · CURRICULUM VITAE DATE PREPARED: June 2nd, 2016 PERSONAL...
29
CURRICULUM VITAE DATE PREPARED: June 2nd, 2016 PERSONAL INFORMATION Name: Maurice Alan Brookhart Office Address: Department of Epidemiology UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill McGavran-Greenberg, CB # 7435 Chapel Hill, NC 27599-7435 EDUCATION 2002 Ph.D. (Biostatistics), University of California, Berkeley 1996 M.A. (Biostatistics), University of California, Berkeley 1994 M.A.M.S (Applied Math), University of Georgia 1990 B.A., University of North Carolina, Chapel Hill PROFESSIONAL EXPERIENCE Academic Appointments 2015- Professor, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC 2015- Adjunct Professor, Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, UNC Chapel Hill, Chapel Hill, NC 2010- Adjunct Associate Professor, Department of Medicine, School of Medicine, UNC Chapel Hill, Chapel Hill, NC 2009-2014 Associate Professor, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC 2008-2009 Assistant Professor of Medicine, Harvard Medical School, Boston MA 2003-2008 Instructor in Medicine, Harvard Medical School, Boston, MA Other Professional Positions and Major Visiting Appointments 2014- Honorary Professor of Clinical Epidemiology, University of Aarhus, Aarhus, Denmark. 2013-present Member, International Scientific Academic Advisory Board of iHope, Kyoto, Japan 2011-present Chair, Scientific Advisory Board, RxAnte, Inc 2010-present Fellow, Cecil G. Sheps Center for Health Services Research 2009 Consultant, Kaiser Permanente Center for Health Research 2008-present Consultant, World Health Information Science Consultants 2008-2009 Consultant, Chronic Disease Research Group, Minneapolis, MN 2008-2010 Member, Interfaculty Initiative on Medications and Society, Harvard University 2007-2008 Consultant, McKesson Health Solutions 2005-present External Member, Working Group in Pharmacoepidemiology, Therapeutics Initiative, University of British Columbia at Vancouver, Vancouver, BC
Transcript of CURRICULUM VITAE - sph.unc.edu · CURRICULUM VITAE DATE PREPARED: June 2nd, 2016 PERSONAL...
CURRICULUM VITAE
DATE PREPARED: June 2nd, 2016
PERSONAL INFORMATION
Name: Maurice Alan Brookhart Office Address: Department of Epidemiology
UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill McGavran-Greenberg, CB # 7435 Chapel Hill, NC 27599-7435
EDUCATION
2002 Ph.D. (Biostatistics), University of California, Berkeley 1996 M.A. (Biostatistics), University of California, Berkeley 1994 M.A.M.S (Applied Math), University of Georgia 1990 B.A., University of North Carolina, Chapel Hill
PROFESSIONAL EXPERIENCE
Academic Appointments
2015- Professor, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2015- Adjunct Professor, Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, UNC Chapel Hill, Chapel Hill, NC
2010- Adjunct Associate Professor, Department of Medicine, School of Medicine, UNC Chapel Hill, Chapel Hill, NC
2009-2014 Associate Professor, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2008-2009 Assistant Professor of Medicine, Harvard Medical School, Boston MA 2003-2008 Instructor in Medicine, Harvard Medical School, Boston, MA
Other Professional Positions and Major Visiting Appointments
2014- Honorary Professor of Clinical Epidemiology, University of Aarhus, Aarhus, Denmark.
2013-present Member, International Scientific Academic Advisory Board of iHope, Kyoto, Japan
2011-present Chair, Scientific Advisory Board, RxAnte, Inc 2010-present Fellow, Cecil G. Sheps Center for Health Services Research 2009 Consultant, Kaiser Permanente Center for Health Research 2008-present Consultant, World Health Information Science Consultants 2008-2009 Consultant, Chronic Disease Research Group, Minneapolis, MN
2008-2010 Member, Interfaculty Initiative on Medications and Society, Harvard University
2007-2008 Consultant, McKesson Health Solutions
2005-present External Member, Working Group in Pharmacoepidemiology,
Therapeutics Initiative, University of British Columbia at Vancouver, Vancouver, BC
June 2nd, 2016
2
2004-2005 Consultant, World Health Organization, Geneva, Switzerland 2003-2009 Biostatistician, Brigham and Women's Hospital, Boston, MA 1997-2003 Statistical Consultant, Meridian Software, Inc., Raleigh, NC
AWARDS
1995 Regents Fellowship, University of California at Berkeley 1994-1994 Phi Kappa Phi, University of Georgia 1993-1993 Beta Gamma Sigma, University of Georgia 1992-1994 Regents Award, University of Georgia
BIBLIOGRAPHY
Refereed Papers/Articles
1. Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol. 2016 Feb 25.
2. Gilbertson DT, Bradbury BD, Wetmore JB, Weinhandl ED, Monda KL, Liu J, Brookhart MA, Gustafson SK, Roberts T, Collins AJ, Rothman KJ. Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):269-77.
3. Freburger JK, Ellis AR, Wang L, Butler AM, Kshirsagar AV, Winkelmayer WC, Brookhart MA. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis. Am J Kidney Dis. 2016 Feb;67(2):271-82.
4. Layton JB, Hansen MK, Jakobsen CJ, Kshirsagar AV, Andreasen JJ, Hjortdal VE, Rasmussen BS, Simpson RJ, Brookhart MA, Christiansen CF. Statin initiation and acute kidney injury following elective cardiovascular surgery: a population cohort study in Denmark. Eur J Cardiothorac Surg. 2016 Mar;49(3):995-1000.
5. Brookhart MA, Freburger JK, Ellis AR, Winkelmayer WC, Wang L, Kshirsagar AV. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients. Am J Kidney Dis. 2016 Jan;67(1):119-27.
6. Reams BD, Dluzniewski PJ, Do TP, Yue SV, Bradbury BD, Kshirsagar AV, Brookhart MA Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design. BMC Nephrol. 2015 Oct 29; 16:175.
7. Cai M, Kappelman MD, Girman CJ, Jain N, Stürmer T, Brookhart MA. Trends and Determinants of Oral Anti-Diabetic Initiation in Youth with Suspected Type 2 Diabetes. PLoS One. 2015 Oct 28;10(10).
8. Trends in Anemia Management in Hemodialysis Patients with Cancer. Butler AM, Kshirsagar AV, Olshan AF, Nielsen ME, Wheeler SB, Brookhart MA. Am J Nephrol. 2015;42(3):206-15.
9. Airy M, Mandayam S, Mitani AA, Chang TI, Ding VY, Brookhart MA, Goldstein BA, Winkelmayer WC. Comparative outcomes of predominant facility-level use of ferumoxytol versus otherintravenous iron formulations in incident hemodialysis patients. Airy M, Mandayam S, Mitani AA, Chang TI, Ding VY, Brookhart MA, Goldstein BA, Winkelmayer WC. Nephrol Dial Transplant. 2015 Dec;30(12):2068-75.
June 2nd, 2016
3
10. Mack CD, Brookhart MA, Glynn RJ, Meyer AM, Carpenter WR, Sandler RS, Stürmer T. Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis. Epidemiology. 2015 Sep;26(5):690-9.
11. Wyss R, Ellis AR, Brookhart MA, Jonsson Funk M, Girman CJ, Simpson RJ Jr, Stürmer T. Matching on the disease risk score in comparative effectiveness research of new treatments. Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):951-61.
12. Korhonen MJ, Halonen JI, Brookhart MA, Kawachi I, Pentti J, Karlsson H, Kivimäki M, Vahtera J. Childhood adversity as a predictor of non-adherence to statin therapy in adulthood. PLoS One. 2015 May 26;10(5):e0127638.
13. Layton JB, Meier CR, Sharpless JL, Stürmer T, Jick SS, Brookhart MA. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med. 2015 Jul;175(7):1187-96.
14. Pomerantz H, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin G, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri J, Lew R, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. JAMA Dermatol. 2015 Sep;151(9):952-60.
15. Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul;66(1):106-13.
16. Jensen ET, Cook SF, Allen JK, Logie J, Brookhart MA, Kappelman MD, Dellon ES.Enrollment factors and bias of disease prevalence estimates in administrative claims data. Ann Epidemiol. 2015 Jul;25(7):519-525.
17. Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015 May; 26(5):1515-24. doi: 10.1007/s00198-014-3022-9. PMID: 25600474.
18. McGrath LJ, Ellis AR, Brookhart MA. Controlling time-dependent confounding by health status and frailty: restriction versus statistical adjustment. Am J Epidemiol. 2015 Apr 12: PMID: 25868551
19. Li J, Fine J, Brookhart A. Instrumental variable additive hazards models. Biometrics. 2015 Mar;71(1):122-30. Epub 2014 Oct 8
20. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015 Apr 10;4(4); e001798. doi: 10.1161/JAHA.115.001798. PMID: 25862791.
21. Henegar CE, Westreich DJ, Maskew M, Miller WC, Brookhart MA, Van Rie A. Effect of pregnancy and the postpartum period on adherence to antiretroviral therapy among HIV-infected women established on treatment. J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):477-80. doi:10.1097/QAI.0000000000000501. PMID: 25559590.
22. Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes. JAMA Pediatr. 2015 Mar 30. doi: 10.1001/jamapediatrics.2015.74. PMID: 25822253.
23. McGrath LJ, Brookhart MA. On-label and off-label use of high dose influenza vaccine in the United States, 2010-2012. Hum Vaccin Immunother. 2015 Mar 4;11(3):537-44. doi: 10.1080/21645515.2015.1011026. PMID: 25751700.
24. Henegar CE, Westreich D, Maskew M, Brookhart MA, Miller WC, Majuba P, Van Rie A. Comparison of pharmacy-based measures of adherence to antiretroviral therapy as
June 2nd, 2016
4
predictors of virological failure. AIDS Behav. 2015 Apr;19(4):612-8. doi: 10.1007/s10461-014-0953-2. PMID: 25433652.
25. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015 Apr 15;115(8):1095-101. doi: 10.1016/j.amjcard.2015.01.539. PMID: 25724781.
26. Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, Brookhart MA. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009. Am J Kidney Dis. 2015 Feb 6. pii: S0272-6386(15)00017-7. doi: 10.1053/j.ajkd.2014.12.013. PMID: 25662835.
27. MA, Winkelmayer WC, Eaton CB, Heiss G, Fine JP. Adiposity patterns and the risk for ESRD in postmenopausal women. Clin J Am Soc Nephrol. 2015 Feb 6;10(2):241-50. doi: 10.2215/CJN.02860314. PMID: 25452225.
28. Cole SR, Hudgens MG, Brookhart MA, Westreich D. Risk. Am J Epidemiol. 2015 Feb 15;181(4):246-50. doi: 10.1093/aje/kwv001. PMID: 25660080.
29. Riis AH, Johansen MB, Jacobsen JB, Brookhart MA, Stürmer T, Støvring H. Short look-back periods in pharmacoepidemiologic studies of new users of antibiotics and asthma medications introduce severe misclassification. Pharmacoepidemiol Drug Saf. 2015 Jan 20. doi: 10.1002/pds.3738. PMID: 25601142.
30. Dusetzina SB, Brookhart MA, Maciejewski ML. Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies. Health Serv Res. 2015 Jan 19. doi: 10.1111/1475-6773.12279. PMID: 25598384.
31. Wyss R, Ellis AR, Lunt M, Brookhart MA, Glynn RJ, Stürmer T. Model misspecification when excluding instrumental variables from PS models in settings where instruments modify the effects of covariates on treatment. Epidemiol Method. 2014 Dec;3(1):83-96. PMID: 25667819.
32. Flythe JE, Brookhart MA. Fluid management: the challenge of defining standards of care. Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2033-5. doi: 10.2215/CJN.10341014. Epub 2014 Nov 6. PMID: 25376766.
33. Faurot KR, Jonsson Funk M, Pate V, Brookhart MA, Patrick A, Hanson LC, Castillo WC, Stürmer T. Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol Drug Saf. 2015 Jan;24(1):59-66. doi: 10.1002/pds.3719. Epub 2014 Oct 21. PMID: 25335470.
34. Wyss R, Lunt M, Brookhart MA, Glynn RJ, Stürmer T. Reducing Bias Amplification in the Presence of Unmeasured Confounding Through Out-of-Sample Estimation Strategies for the Disease Risk Score. J Causal Inference. 2014 Sep 1;2(2):131-146. PMID: 25313347.
35. Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman HJ, Dormuth CR Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort. BMJ Open. 2014 Sep 30;4(9):e005532. doi: 10.1136.
36. Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA. Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study. BMC Nephrol. 2014 Sep 22;15:154. doi: 10.1186/1471-2369-15-154.
37. Brookhart MA, Todd JV, Li X, Reams BD, Pate V, Kshirsagar AV. Estimation of biomarker distributions using laboratory data collected during routine delivery of medical care. Ann Epidemiol. 2014 Oct;24(10):754-61.
38. Wyss R, Ellis AR, Brookhart MA, Girman CJ, Jonsson Funk M, LoCasale R, Stürmer T. The Role of Prediction Modeling in Propensity Score Estimation: An Evaluation of
June 2nd, 2016
5
Logistic Regression, bCART, and the Covariate-Balancing Propensity Score. Am J Epidemiol. 2014 Aug 20.
39. Raghunathan K, Shaw A, Nathanson B, Stürmer T, Brookhart A, Stefan MS, Setoguchi S, Beadles C, Lindenauer PK. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med. 2014 Jul;42(7):1585-91.
40. *Li X, Sturmer, TS, Brookhart MA. Evidence of sample use among new users of statins: implication for pharmacoepidemiology. Med Care. 2014 Sep;52(9):773-80.
41. Wyss R, Girman CJ, LoCasale RJ, Brookhart MA, Stürmer T. Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):77-85.
42. Cole SR, Lau B, Eron JJ, Brookhart MA, Kitahata MM, Martin JN, Mathews WC, Mugavero MJ; for the CNICS Research Network. Estimation of the Standardized Risk Difference and Ratio in a Competing Risks Framework: Application to Injection Drug Use and Progression to AIDS After Initiation of Antiretroviral Therapy. Am J Epidemiol. 2014 Jun 24.
43. *Overman RA, Freburger JK, Assimon MM, Li X, Brookhart MA. Observation stays in administrative claims databases: underestimation of hospitalized cases. Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):902-10.
44. Polinski JM, Brookhart MA, Ayanian JZ, Katz JN, Kim SC, Lii J, Tonner C, Yelin E, Solomon DH. Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying anti-rheumatic drug receipt. Arthritis Care Res (Hoboken). 2014 Mar 24
45. Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol. 2014 Jun;123(6):1177-84
46. Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM. Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States (1995-2010). JAMA Intern Med. 2014 Mar 3.
47. *Panozzo CA, Becker-Dreps S, Pate V, Weber DJ, Jonsson Funk M, Stürmer T, Brookhart MA. Direct, Indirect, Total, and Overall Effectiveness of the Rotavirus Vaccines for the Prevention of Gastroenteritis Hospitalizations in Privately Insured US Children, 2007-2010. Am J Epidemiol. 2014 Apr 1;179(7):895-909
48. Beadles CA, Hassmiller Lich K, Viera AJ, Greene SB, Brookhart MA, Weinberger M. A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals. BMJ Open. 2014 Feb 12;4(2)
49. Stürmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014 Feb 13.
50. Solomon DH, Tonner C, Lu B, Kim SC, Ayanian JZ, Brookhart MA, Katz JN, Yelin E. Predictors of stopping and starting disease modifying anti-rheumatic drugs for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Jan 27.
51. *Layton JB, Li D, Meier CR, Sharpless J, Stürmer T, Jick SS, Brookhart MA. Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000-2011. J Clin Endocrinol Metab. 2014 Jan 1.
52. Fang G, Robinson JG, Lauffenburger J, Roth MT, Brookhart MA. Prevalent but moderate variation across small geographic regions in patient nonadherence to evidence-based preventive therapies in older adults after acute myocardial infarction. Med Care. 2014 Mar;52(3):185-93.
June 2nd, 2016
6
53. Reams BD, O'Malley CD, Critchlow CW, *Lauffenburger JC, Brookhart MA. Changing patterns of use of osteoporosis medications in the years after launch: implications for comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):251-60.
54. Yelin E, Tonner C, Kim SC, Katz JN, Ayanian JZ, Brookhart MA, Solomon DH. Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in Rheumatoid Arthritis:A Longitudinal Study. Arthritis Care Res (Hoboken). 2013 Dec 10.
55. *McGrath LJ, Becker-Dreps S, Pate V, Brookhart MA. Trends in antibiotic treatment of acute otitis media and treatment failure in children, 2000-2011. PLoS One. 2013 Dec 4;8(12):e81210.
56. Beadles CA, Hassmiller Lich K, Viera AJ, Greene SB, Brookhart MA, Weinberger M. Patient-centered medical homes and oral anticoagulation therapy initiation. Med Care Res Rev. 2014 Apr;71(2):174-91.
57. Le HV, Poole C, Brookhart MA, Schoenbach VJ, Beach KJ, Layton JB, Stürmer T. Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC Med Res Methodol. 2013 Nov 19;13:142.
58. Balasubramanian A, Brookhart MA, Goli V, Critchlow CW. Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med. 2013 Nov 6;6:839-48.
59. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One. 2013 Nov 1;8(11).
60. *Butler AM, Kshirsagar AV, Brookhart MA. Opioid Use in the US Hemodialysis Population. 2014 Jan;63(1):171-3. [
61. *Hamra GB, Semelka RC, Burke LM, Pate V, Brookhart MA. Trends in Diagnostic CT Among Fee-For-Service Enrollees, 2000-2011. J Am Coll Radiol. 2013 Sep 12. [Epub ahead of print]
62. Schoenfisch AL, Lipscomb HJ, Marshall SW, Casteel C, Richardson DB, Brookhart MA, Cameron W. Declining rates of work-related overexertion back injuries among union drywall installers in Washington State, 1989-2008: Improved work safety or shifting of care? Am J Ind Med. 2013 Aug 19 [Epub ahead of print]
63. *Panozzo CA, Becker-Dreps S, Pate V, Jonsson Funk M, Stürmer T, Weber DJ, Brookhart MA. Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006-2010. PLoS One. 2013:16;8(9).
64. Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):604-11.
65. Sauer BC, Brookhart MA, Roy J, Vanderweele T. A review of covariate selection for non-experimental comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013 Sep 5
66. *Costa NA, Kshirsagar AV, Wang L, Detwiler RK, Brookhart MA. Pretransplantation Erythropoiesis-Stimulating Agent Hyporesponsiveness Is Associated with Increased Kidney Allograft Failure and Mortality. Transplantation. 2013 Aug 26. [Epub ahead of print]
67. *Layton JB, Brookhart MA, Jonsson Funk M, Simpson RJ Jr, Pate V, Stürmer T, Kshirsagar AV. Acute kidney injury in statin initiators .Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1061-70.
June 2nd, 2016
7
68. *Beaubrun AC, Kilpatrick RD, Freburger JK, Bradbury BD, Wang L, Brookhart MA. Temporal Trends in Fracture Rates and Postdischarge Outcomes among Hemodialysis Patients. J Am Soc Nephrol. 2013; 24(9):1461-9.
69. *McGrath LJ, Cole SR, Kshirsagar AV, Weber DJ, Stürmer T, Brookhart MA. Hospitalization and Skilled Nursing Care are Predictors of Influenza Vaccination Among Patients on Hemodialysis: Evidence of Confounding by Frailty. Med Care. 2013 Aug 21.
70. Ellis AR, Brookhart MA. Approaches to inverse-probability-of-treatment-weighted estimation with concurrent treatments. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S51-6
71. Brookhart MA, Freburger JF, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Intravenous Iron Supplementation Practices and Infection Risk in Hemodialysis Patients. J Am Soc Nephrol, 2013; 24(7):1151-8
72. *Lauffenburger JC, Balasubramanian A, Farley JF, Critchlow CW, O'Malley CD, Roth MT, Pate V, Brookhart MA. Completeness of pharmacy claims in commercial insurance data. Pharmacoepidemiol Drug Saf. 2013; 22(8):899-906
73. *Layton JB, Kshirsagar AV, Simpson RJ Jr, Pate V, Jonsson Funk M, Stürmer T, Brookhart MA. Effect of statin use on acute kidney injury risk following coronary artery bypass grafting. Am J Cardiol. 2013 Mar 15;111(6):823-8.
74. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. The Comparative Short-term Effectiveness of Iron Dosing and Formulations in US Hemodialysis Patients. Am J Med. 2013 Apr 15.
75. Brouwer ES, Napravnik S, Eron JJ Jr, Simpson RJ, Brookhart MA, Stalzer B, Vinikoor M, Floris-Moore M, Stürmer T. Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort. Med Care. 2013 Mar 20.
76. Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, Sandler RS, Stürmer T. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf. 2013 Jan 7.
77. Naimi AI, Cole SR, Hudgens MG, Brookhart MA, Richardson DB. Assessing the component associations of the healthy worker survivor bias: occupational asbestos exposure and lung cancer mortality. Ann Epidemiol. 2013 Jun;23(6):334-41.
78. *Choi B, Fine JP, Brookhart MA. Practicable confidence intervals for current status data. Stat in Med. 2013 Apr 15; 32(8):1419-28.
79. Lund JL, Stürmer T, Sanoff HK, Brookhart MA, Sandler RS, Warren JL. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer. 2013 Jun 1;119(11):2038-47.
80. Liu W, Brookhart MA, Schneeweiss S, Mi X, Setoguchi S. Implications of M-bias in epidemiologic studies: a simulation study. Am J Epidemiol. 2012; 176(10):938-48.
81. Wyss R, Girman CJ, Locasale RJ, Brookhart MA, Stürmer T. Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiol Drug Saf. 2012 [epub ahead of print]
82. Platt RW, Brookhart MA, Cole SR, Westreich D, Schisterman EF. An information criterion for marginal structural models. Stat Med. 2012 Sep 12. [Epub ahead of print]
83. *Beaubrun AC, Brookhart MA, Sleath B, Wang L, Kshirsagar AV. Trends and Variations in Intravenous Vitamin D Use among Hemodialysis Patients in the United States. Ren Fail. 2012 Oct 22. [Epub ahead of print]
84. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA. Changing patterns of anemia management in US hemodialysis patients. Am J Med. 2012 Sep;125(9):906-14.
85. Brookhart MA, Walker AM, Lu Y, Polakowski L, Li J, Paeglow C, Puenpatom T, Izurieta H, Daniel GW. Characterizing vaccine-associated risks using cubic smoothing splines. Am J Epidemiol. 2012;176(10):949-57.
June 2nd, 2016
8
86. *McGrath LS, Kshirsagar AV, Cole SR, Wang L, Weber DJ, Stürmer TS, Brookhart MA. Evaluating influenza vaccine effectiveness among hemodialysis patients using a natural experiment. Arch of Int Med, 2012;172(7):548-54.
87. Solomon DH, Iversen MD, Avorn J, Gleeson T, Brookhart MA, Patrick AR, Rekedal L, Shrank WH, Lii J, Losina E, Katz JN. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med. 2012 Mar 26;172(6):477-83.
88. Kilpatrick RD, Gilbertson D, Brookhart MA, Polley E, Rothman KJ, Bradbury BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions. Pharmacoepidemiol Drug Saf. 2012[epub ahead of press]
89. Polinski JM, Brookhart MA, Glynn RJ, Schneeweiss S. Medicare Part D's Impact on Antipsychotic Drug Use and Costs Among Elderly Patients Without Prior Drug Insurance. J Clin Psychopharmacol. 2012 Feb;32(1):3-10.
90. Winkelmayer WC, Hurley MP, Liu J, Brookhart MA. Altitude and the risk of cardiovascular events in incident US dialysis patients. Nephrol Dial Transplant. 2012; 27(6):2411-7.
91. Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. Identifying Specific Chemotherapeutic Agents in Medicare Data: A Validation Study. Med Care. 2011 Nov 10. [Epub ahead of print]
92. Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res. 2011 Oct 19 [epub ahead of print]
93. Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, Schneeweiss S. Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. Am J Epidemiol. 2011;174(9):1089-99.
94. *Stedman MR, Lew RA, Losina E, Gagnon DR, Solomon DH, Brookhart MA. A comparison of statistical approaches for physician-randomized trials with survival outcomes. Contemp Clin Trials. 2011 Sep 6. [Epub ahead of print]
95. Patrick AR, Shrank WH, Glynn RJ, Solomon DH, Dormuth CR, Avorn J, Cadarette SM, Mogun H, Brookhart MA. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health. 2011;14(4):513-20.
96. Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA, Winkelmayer WC. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis. 2011 Sep;58(3):409-17.
97. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011 Jun 15;173(12):1404-13
98. Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly Robust Estimation of Causal Effects. Am J Epidemiol. 2011; 20(6): 551-9.
99. *Stedman MR, Gagnon DR, Lew RA, Jung SH, Losina E, Brookhart MA. A SAS macro for a clustered logrank test. Comput Methods Programs Biomed. 2011 Nov;104(2):266-70
100. Parikh S, Brookhart MA, Stedman M, Avorn J, Mogun H, Solomon DH. Correlations of nursing home characteristics with prescription of osteoporosis medications. Bone. 2011 May 1;48(5):1164-1168.
101. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic
June 2nd, 2016
9
medications in older adults admitted to nursing homes. CMAJ. 2011 Apr 19;183(7):E411-9.
102. Costenbader KH, Desai A, Alarcón GS, Hiraki L, Shaykevich T, Brookhart MA, Massarotti E, Lu B, Solomon DH, Winkelmayer WC. Trends in the incidence, demographics and outcomes of end-stage renal disease due to lupus nephritis in the U.S., 1995-2006. Arthritis Rheum. 2011 Mar 28
103. R Curtis J, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ. Placebo Adherence, Clinical Outcomes, and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. Med Care. 2011 May; 49(5):427-435.
104. Choudhry NK, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, Berman C, Jan S, Liu J, Lii J, Brookhart MA, Mahoney JJ, Shrank WH. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995-2001.
105. Brookhart MA, Bradbury BD, Avorn J, Schneeweiss S, Winkelmayer WC. The Effect of Altitude Change on Anemia Treatment Response in Hemodialysis Patients. Am J Epidemiol. 2011 Feb 23. [Epub ahead of print]
106. Brookhart MA, Solomon DH, Glynn RJ, Ridker PM. Effect of Rosuvastatin on Hemoglobin Levels in Patients With Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial. J Clin Pharmacol. 2010 Dec 28
107. Solomon DH, Brookhart MA, Tsao P, Sundaresan D, Andrade SE, Mazor K, Yood R. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int. 2011 Jun;22(6):1737-43.
108. *Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011 Mar;22(3):943-54.
109. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011 Feb;22(2):349-57.
110. Winkelmayer WC, Stedman MR, Pogantsch M, Wieninger P, Bucsics A, Asslaber M, Bauer R, Burkhardt T, Schautzer A, Brookhart MA; Pharmacoeconomics Advisory Council of the Main Association of Austrian Sickness Funds. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria. Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):57-65.
111. Shrank WH, Choudhry NK, Fischer MA, Avorn J, Powell M, Schneeweiss S, Liberman JN, Dollear T, Brennan TA, Brookhart MA. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010 Nov 16;153(10):633-40.
112. Cutrona SL, Choudhry NK, Stedman M, Servi A, Liberman JN, Brennan T, Fischer MA, Brookhart MA, Shrank WH. Physician effectiveness in interventions to improve cardiovascular medication adherence: a systematic review. J Gen Intern Med. 2010 Oct;25(10):1090-6.
113. Choudhry NK, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, Berman C, Jan S, Liu J, Lii J, Brookhart MA, Mahoney JJ, Shrank WH. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010 Nov;29(11):1995-2001.
114. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS, Brookhart MA, Fischer MA. State generic substitution laws can lower drug outlays under medicaid. Health Aff (Millwood). 2010: 29(7):1383-90.
115. Brookhart MA, Stürmer T, Glynn RJ, Rassen JA, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care, 2010 Jun; S114-20.
June 2nd, 2016
10
116. *Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporosis Int 2010; in press.
117. Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, Solomon DH. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010, in press.
118. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010: 26;70(5):605-21
119. Brookhart MA, Schneeweiss S, Avorn J, Bradbury B, Liu J, Winkelmayer W. Comparative mortality risk of anemia management practices in end-stage renal disease. JAMA. 2010; 303(9): 857-64.
120. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf. 2010 Mar 30. [Epub ahead of print]
121. Winkelmayer WC, Asslaber M, Bucsics A, Burkhardt T, Schautzer A, Wieninger P, Pogantsch M, Brookhart MA. Impact of reimbursement changes on statin use among patients with diabetes in Austria. Wien Klin Wochenschr. 2010 Feb;122(3-4):89-94.
122. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, Solomon D, Brookhart MA, Choudhry NK. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196-202.
123. Solomon DH, Gleeson T, Iversen M, Avorn J, Brookhart MA, Lii J, Losina E, May F, Patrick A, Shrank WH, Katz JN. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial. Osteoporos Int. 2010 Jan;21(1):137-44.
124. Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang O, Rothman KJ. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep;54(3):554-60.
125. Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009;18(10):932-40.
126. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, Solomon DH. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009; 15(7):457-64.
127. *Stedman MR, Gagnon DR, Lew RA, Solomon DH, Brookhart MA. A SAS Macro for Cluster-Randomized Permutation Testing. Computer Methods and Programs in Biomedicine, 2009; 95(1):89-94.
128. Schneeweiss S, Rassen J, Avorn J, Mogun H, Brookhart MA. High dimensional propensity score adjustment. Epidemiology, 2009; 20(4):512-22.
129. Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Levin R, Solomon DH. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int., Osteoporos Int. 2009; 20(10):1735-47.
130. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009 Dec;62(12):1226-32.
131. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables II: instrumental variable application in 25 variations, the physician prescribing
June 2nd, 2016
11
preference generally was strong and reduced covariate imbalance. J Clin Epidemiol. 2009 Dec; 62(12):1233-41.
132. Shrank WH, Choudhry NK, Solomon DH, Snedden TM, Lee TH, Glynn RJ, Brown TV, Jolda C, Spetman M, Brookhart MA, Schneeweiss S, Avorn J. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009;157(4):613-9.
133. Dormuth C, Patrick AR, Wright JM, Brookhart MA. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009 119(15):2051-9.
134. Winkelmayer WC, Liu J, Brookhart MA. The effect of altitude on mortality in ESRD. JAMA. 2009;301(5):508-12.
135. Shrank WH, Gleason PP, Canning C, Walters C, Heaton AH, Jan S, Patrick A, Brookhart MA, Schneeweiss S, Solomon DH, Avorn J, Choudhry NK. Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications? An Evaluation of the Target Pharmacy Label. J Gen Intern Med. 2009; 24(5):570-8
136. Gellad WF, Choudhry NK, Friedberg MW, Brookhart MA, Haas JS, Shrank WH. Variation in Drug Prices at Pharmacies: Are Prices Higher in Poorer Areas? Health Serv Res. 2009; 44(2 Pt 1):606-17.
137. Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS. Assessing Residual Confounding of the Association between Antipsychotic Medications and Risk of Death using Survey Data. CNS Drugs. 2009; 23(2):171-80.
138. Rassen JA, Schneeweiss S, Glynn RJ, Mittleman MA, Brookhart MA. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am J Epidemiol. 2009; 169(3):273-84
139. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008; 300(21):2514-26.
140. Fischer MA, Vogeli C, Stedman M, Ferris T, Brookhart MA, Weissman JS. Effect of electronic prescribing with formulary decision support on medication use and cost. Arch Intern Med. 2008;168(22):2433-9.
141. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation. 2008;118(18):1785-92.
142. Brookhart MA, Rothman KJ. Simple estimators of the intensity of seasonal occurrence. BMC Med Res Methodol. 2008;8(1):67.
143. *Stedman MR, Gagnon DR, Lew RA, Solomon DH, Brookhart MA. An evaluation of statistical approaches for analyzing physician-randomized quality improvement interventions. Contemp Clin Trials. 2008;29(5):687-95.
144. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, Mehta J, Winkelmayer WC. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008;19(7):1389-95.
145. Choudhry NK, Brennan T, Toscano M, Spettell C, Glynn RJ, Rubino M, Schneeweiss S, Brookhart MA, Fernandes J, Mathew S, Christiansen B, Antman EM, Avorn J, Shrank WH. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008;156(1):31-6.
146. *Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR, Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008;148(9):637-46.
June 2nd, 2016
12
147. *Goodson NJ, Brookhart MA, Symmons DP, Silman AJ, Solomon DH. Non-Steroidal Anti-Inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis. 2008; 68(3):367-72.
148. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101(7):960-6.
149. Setoguchi S, Schneeweiss S, Brookhart MA, Glynn RJ, Cook EF. Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf. 2008; 17(6):546-55.
150. *Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol. 2008;35(2):319-26.
151. Dormuth CR, Maclure M, Glynn RJ, Neumann P, Brookhart MA, Schneeweiss S. Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther. 2008;30P1:1038-1050.
152. *van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008;26(1):145-153.
153. Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects. International Journal of Biostatistics. 2007;3(1):14.
154. Wang PS, Schneeweiss S, Setoguchi S, Patrick A, Avorn J, Mogun H, Choudhry NK, Brookhart MA. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27(6):707-710.
155. Solomon DH, Katz JN, Carrino JS, Levin R, Brookhart MA. Percutaneous vertebroplasty among low-income Medicare beneficiaries. Spine. 2007;32(25):2910-4.
156. Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, Rothman KJ, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10 Supl 2):S131-42.
157. Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schneeweiss S. Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care. 2007;45(10 Supl 2):S116-22.
158. Glynn RJ, Brookhart MA, Stedman M, Avorn J, Solomon DH. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers. Med Care. 2007;45(10 Supl 2):S38-43.
159. Brookhart MA, Avorn J, Polinksi JM, Brown TV, Mogun H, Solomon DH. The medical license number accurately identifies the prescribing physician in a large pharmacy claims database. Med Care. 2007;45(9):907-910.
160. Shrank WH, Stedman M, Ettner SL, DeLapp D, Dirstine J, Brookhart MA, Fischer MA, Avorn J, Asch SM. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. J Gen Intern Med. 2007;22(9):1298-304.
161. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2007; 67(5):609-13.
162. Solomon DH, Katz JN, Finkelstein JS, Polinski JM, Stedman M, Brookhart MA, Arnold M, Gauthier S, Avorn J. Osteoporosis Improvement: a large scale randomized controlled trial of patient and primary care physician education. J Bone Miner Res. 2007; 22(11):1808-15.
June 2nd, 2016
13
163. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007; 166(3):348-54.
164. Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade? JAMA. 2007;297(16):1810-8.
165. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, van Wijk BL, Cadarette SM, Canning CF, Solomon DH. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847-52.
166. van Wijk BL, Avorn J, Solomon DH, Klungel OH, Heerdink ER, de Boer A, Brookhart MA. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. J Hypertens. 2007;25(3):689-97.
167. Solomon DH, Polinski JM, Stedman M, Truppo C, Breiner L, Egan C, Jan S, Patel M, Weiss TW, Chen YT, Brookhart MA. Improving care of patients at-risk for osteoporosis: a randomized controlled trial. J Gen Intern Med. 2007;22(3):362-367.
168. Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007;120(3):251-6.
169. Schneeweiss S, Setoguchi S, Brookhart MA, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-32.
170. Solomon DH, Polinski JM, Truppo C, Egan C, Jan S, Patel M, Weiss TW, Chen YT, Brookhart MA. Access to bone mineral density testing in patients at risk for osteoporosis. Osteoporos Int. 2006;17(12):1749-54.
171. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(21):2307-13.
172. Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum. 2006;54(11):3390-8.
173. Wang PS, Brookhart MA, Setoguchi S, Patrick AR, Schneeweiss S. Psychotropic medication use for behavioral symptoms of dementia. Curr Neurol Neurosci Rep. 2006;6(6):490-5.
174. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol. 2006;1(4):796-801.
175. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-56.
176. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart MA, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006;28(6):964-78; discussion 962-3.
177. Winkelmayer WC, Benner JS, Glynn RJ, Schneeweiss S, Wang PS, Brookhart MA, Levin R, Jackson JD, Avorn J. Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making. 2006;26(3):247-54.
178. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J. Kidney function and use of recommended medications after myocardial infarction in elderly patients. CJASN. 2006: pp. 796-801.
June 2nd, 2016
14
179. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17(3):268-75.
180. Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res. 2006;21(5):765-71.
181. Brookhart MA, Solomon DH, Wang P, Glynn RJ, Avorn J, Schneeweiss S. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006;59(1):18-25.
182. Brookhart MA, van der Laan MJ. A semiparametric model selection criterion with applications to the marginal structural model. Computational Statistics and Data Analysis. 2006;50. (2):475-498.
183. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-41.
184. Polinski JM, Brookhart MA, Katz JN, Arnold M, Kristeller J, Trombetta D, Tadduni ME, Golomb MJ, Solomon DH. Educational outreach (academic detailing) regarding osteoporosis in primary care. Pharmacoepidemiol Drug Saf. 2005;14(12):843-50.
185. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414-9.
186. Wang PS, Avorn J, Brookhart MA, Mogun H, Schneeweiss S, Fischer MA, Glynn RJ. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension. 2005;46(2):273-9.
187. Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005;161(9):891-8.
188. Wang PS, Schneeweiss S, Brookhart MA, Glynn RJ, Mogun H, Patrick AR, Avorn J. Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005;25(2):118-26.
189. Colford JM, Wade TJ, Sandhu SK, Wright CC, Lee S, Shaw S, Fox K, Burns S, Benker A, Brookhart MA, van der Laan M, Levy DA. A randomized, controlled trial of in-home drinking water intervention to reduce gastrointestinal illness. Am J Epidemiol. 2005;161(5):472-82.
190. Solomon DH, Brookhart MA, Polinski J, Katz JN, Cabral D, Licari A, Avorn J. Osteoporosis action: design of the healthy bones project trial. Contemp Clin Trials. 2005;26(1):78-94.
191. Eisenberg JN, Lei X, Hubbard AH, Brookhart MA, Colford JM. The role of disease transmission and conferred immunity in outbreaks: analysis of the 1993 Cryptosporidium outbreak in Milwaukee, Wisconsin. Am J Epidemiol. 2005;161(1):62-72.
192. Solomon DH, Brookhart MA, Gandhi TK, Karson A, Gharib S, Orav EJ, Shaykevich S, Licari A, Cabral D, Bates DW. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med. 2004;117(12):919-24.
193. Brookhart MA, Hubbard AE, van der Laan MJ, Colford JM, Eisenberg JN. Statistical estimation of parameters in a disease transmission model: analysis of a Cryptosporidium outbreak. Stat Med. 2002;21(23):3627-38.
194. Eisenberg JN, Brookhart MA, Rice G, Brown M, Colford JM. Disease transmission models for public health decision making: analysis of epidemic and endemic conditions caused by waterborne pathogens. Environ Health Perspect. 2002;110(8):783-90.
June 2nd, 2016
15
195. Shlonsky A, D'Andrade A, Brookhart MA. Submission suggestions for statistical methods. Journal of Social Work Education. 2002;38(1).
196. Needell B, Cuccaro-Alamin S, Brookhart MA, Lee S. Transitions from AFDC to child welfare in California. Children and Youth Services Review. 1999;21(10):815-841.
197. Kolotkin RL, Head S, Brookhart MA. Construct validity of the Impact of Weight on Quality of Life Questionnaire. Obes Res. 1997;5(5):434-41.
198. Head S, Brookhart MA. Lifestyle modification and relapse-prevention training during treatment for weight loss. Behavior Therapy. 1997;28(2):307-321.
*papers lead by students or other trainees for whom I served as a primary advisor for the work being done
OTHER UNREFEREED WORKS
Reviews/Chapters/Editorials/Letters
1. Brookhart MA, McGrath LS. The influenza vaccine in the elderly: a shot in the dark? Arch
Int Med, in press. 2. Stürmer T, Jonsson Funk M, Poole C, Brookhart MA. Nonexperimental comparative
effectiveness research using linked healthcare databases. Epidemiology. 2011 May; 22(3):298-301.
3. Brookhart MA, Patrick AR, Shrank WH, Dormuth CR. Validating studies of adherence through the use of control outcomes and exposures. Am J Hypertens. 2010; 23(2):110.
4. *Stedman MR, Curtin F, Elbourne DR, Kesselheim AS, Brookhart MA. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2009 Dec 21. [Epub ahead of print]
5. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009 Apr 23;360(17):1789-90.
6. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008; 300(21):2514-26.
7 Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology. 2006;17(4):373-4.
Theses
1. Brookhart MA. Computer intensive approaches to four topics in Biostatistics. Berkeley, CA: U. of California;2002.
2. Brookhart MA. Sports power ratings. Athens, GA: U. of Georgia;1995.
Invited Oral Presentations
Local
2013 Estimating treatment effects using variations in medical practice, CER Seminar,
Cecil G. Sheps Center for Health Services Research, UNC Chapel Hill, Chapel Hill, NC
June 2nd, 2016
16
2013 Comparative effectiveness of intravenous iron in hemodialysis patients,
Cardiovascular Epidemiology Seminar, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2013 Confounding and selection bias in non-experimental studies, Healthcare
Epidemiology Seminar, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2012 Challenges in non-experimental comparative effectiveness research, Healthcare
Epidemiology Seminar, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2012 Confounding bias in studies of therapeutics, Healthcare Epidemiology Seminar, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2011 Assessing short-term vaccine-related risks using smoothing splines, AHRQ
NSRA Seminar, Cecil G. Sheps Center for Health Services Research, UNC Chapel Hill, Chapel Hill, NC
2011 Nonexperimental comparative effectiveness research, GlaxoSmithKline, Research Triangle Park, NC
2011 Nonexperimental comparative effectiveness research, UNC School of Pharmacy, UNC Chapel Hill, Chapel Hill, NC
2011 Methods to control confounding bias in studies of therapeutics, Durham VA, Durham, NC
2011 Source of confounding bias in studies of therapeutics, Healthcare Epidemiology Seminar, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2010 Natural experiments and instrumental variables in pharmacoepidemiology.
Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, UNC Chapel Hill, Chapel Hill, NC
2010 Source of confounding bias in studies of therapeutics, Comparative
Effectiveness Seminar, Department of Health Care Policy, UNC Chapel Hill, Chapel Hill, NC
2010 Increase in bias resulting from adjustment for an instrumental variable. Causal Inference Working Group Seminar, UNC Chapel Hill, Chapel Hill, NC
2008 The effect of altitude on erythropoietin dosing: results from a natural crossover experiment, Dept. of Epidemiology, Harvard School of Public Health
2008 Variable selection for propensity score models, Department of Medicine, Brigham and Women's Hospital.
2007 Preference-based instrumental variables in pharmacoepidemiology, Dept. of Biostatistics, Harvard School of Public Health.
2007 The effect of altitude on erythropoietin dosing and achieved hematocrit levels in end-stage renal disease, Brigham and Women's Hospital, Renal Division.
2006 Instrumental variables in pharmacoepidemiology, Brigham and Women's Hospital, Division of Rheumatology.
National
2015 Estimating the effect of preventing non-medically directed treatment
discontinuation using inverse-probability of censoring weighting. Pharmacoepidemiology Seminar. Merck, King of Prussia, PA.
2015 Finite-sample performance of inverse-probability weighted median regression in
the presence of large weights. International Conference on Pharmacoepidemiology, Boston, MA.
2014 Natural experiments in comparative effectiveness. American Society of Nephrology, Annual Meeting, Philadelphia, PA.
2013 Estimating treatment effects using variations in medical practice, Clinical Epidemiology Seminar, Washington University, St. Louis, MO
2013 Uncomfortable Realities in Pharmacoepidemiologic Research, Merck, New Jersey
June 2nd, 2016
17
2013 Current Landscape of Pharmacoepidemiologic Research, Annual Research Seminar, Center for Observational Research, Amgen, Thousand Oaks, CA
2012 Assessing short-term vaccine-related risks using smoothing splines,
Departmental Seminar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
2012 Statistical Methods for Comparative Effectiveness Research, Plenary Lecture,
CER Conference, Baker Institute for Public Policy, Rice University, Houston, Texas
2012 Comparative Effectiveness of Intravenous Iron Formulations in ESRD, AHRQ Annual Methods Meeting, Rockville, MD
2011 Two Topics in Drug Safety Surveillance, Center for Observational Research, Amgen, Thousand Oaks, CA
2011 Marginal Structural Models in Comparative Effectiveness Research, AHRQ Annual Meeting, Bethesda, MD
2011 Performance of a Semi-Automated New User Design for Drug Safety Surveillance, Joint Statistical Meeting, Miami Beach, FL
2011 Current Directions in Medication Adherence Research, Outcomes Research, Pfizer, New York, NY.
2011 Epidemiologic Methods for Comparative Effectiveness with Application to a
Study of Intravenous Iron in End-Stage Renal Disease (CER Method Seminar Series), Pfizer, New York, NY.
2010 Evaluating new user design decisions for drug safety surveillance, Joint Statistical Meeting, Vancouver, British Columbia, Canada.
2010 Evaluating new user design decision of drug safety surveillance, Midwest Biopharmaceutical Statistics Workshop, Ball State University, Muncie, IN.
2009 Empirical evaluation of incident user designs for drug safety surveillance, Observational Medical Outcome Partnership Conference, Bethesda, MD
2009 Comparative Mortality Risk of Anemia Management Practices in ESRD, Department of Biostatistics and Epidemiology, Amgen. Thousand Oaks, CA.
2009 Drug safety assays based on new user designs, Observational Medical
Outcomes Partnership Methods Conference, Foundation for the National Institutes of Health, Bethesda, MD.
2009 The effect of altitude on erythropoietin dosing and response in ESRD, Department of Epidemiology, Amgen.
2009 Instrumental variables in pharmacoepidemiology, Department of Biostatistics and Bioinformatics, Duke University.
2009 The Effect of Altitude of Anemia Management and Outcomes in ESRD, Department of Epidemiology, University of North Carolina.
2009 Adherence to statins and the risk of accidents: A Cautionary Tale, Duke Clinical Research Institute, Duke University. Durham, NC.
2009 The effect of altitude on anemia management and outcomes in ESRD, Department of Epidemiology, Boston School of Public Health, Boston University. (Was selected by BU Epidemiology doctoral students to be invited speaker for an annual talk.)
2009 Variable selection in the presence of residual confounding, AHRQ DEcIDE Investigators Conference, Rockville, MD.
2008 Propensity score methods in pharmacoepidemiology, University of Alabama at Birmingham.
2008 Instrumental variable methods in pharmacoepidemiology, Agency for Health Care Research and Quality.
2008 The Effect of altitude on erythropoietin dosing and response in ESRD, Center for Medicaid and Medicare Services, Department of Health and Human Services.
2007 Assessing the safety of recombinant erythropoietin using instrumental variable
methods, Annual Meeting of the International Biometric Society, Eastern North American Region.
June 2nd, 2016
18
2006 A comparative study of the gastrointestinal safety of selective and non-selective
NSAIDs using instrumental variable methods, Department of Clinical Epidemiology and Biostatistics, University of Pennsylvania.
2006 Instrumental variables in pharmacoepidemiology, AHRQ DEcIDE Investigators Conference.
2006 An overview of statistical methods and study designs for comparative safety and
effectiveness research in pharmacoepidemiology, College of Pharmacy and Department of Epidemiology, University of Iowa.
2006 A comparative study of the gastrointestinal safety of selective and non-selective
NSAIDs using instrumental variables, Arbor Research Collaborative, University of Michigan.
2003 Minimizing the MSE for the parameter of interest in a semiparametric model over
nuisance parameter models using cross validation, Division of Pharmacoepidemiology, Brigham and Women’s Hospital.
2002 Minimizing the MSE for the parameter of interest in a semiparametric model over
nuisance parameter models using cross-validation, Western regional meeting of the Institute for Mathematical Statistics, UCLA.
2002 Profile likelihood estimation of parameters in a transmission dynamic model of
the Milwaukee Cryptosporidium outbreak, Roche Biosciences, Dept. of Biomathematics, Palo Alto, CA.
International
2016 New Approach for Studying the Effects of Medication Non-Adherence. School of Pharmacy, University of Toronto, Toronto, Canada.
2016 Epidemiology in End-Stage Renal Disease: Challenges and Opportunities, Inaugural Lecture, School of Medicine, University of Aarhus, Denmark.
2014 Statistical challenges in comparative effectiveness research (plenary session). Annual New Zealand Statistical Association, Wellington, New Zealand.
2014 Confounding and the new user design. DUEDECIM Annual Meeting, Porvoo, Finland
2014 Do instrumental variables have a role in pharmacoepidemiology? WEON Annual Meeting, Leiden, Netherlands
2014 Addressing confounding in healthcare database research. University of Tokyo, Tokyo, Japan.
2012 Is the healthcare provider a confounder or instrumental variable? Sydney Medical School, The University of Sydney, Sydney, Australia
2012 Comparative Effectiveness Research in the United States, Murdoch Children’s Research Institute, Melbourne, Australia
2012 Is the healthcare provider a confounder or instrumental variable? Victorian Center for Biostatistics, Melbourne, Australia
2012 Comparative Effectiveness Research in the United States, Monash University, Melbourne, Australia
2012 Early Experiences with Laboratory Data, Pre-Conference Workshop, International Conference in Pharmacoepidemiology, Barcelona, Spain
2011 Altitude and outcomes in ESRD, Department of Epidemiology, McGill University, Montreal, Canada
2011 Statistical methods for comparative effectiveness research (invited workshop contributor), International Society for Clinical Biostatistics, Ottawa, Canada
2010 Statistical challenges in pharmacoepidemiology (invited plenary session),
Annual Meeting of the International Society of Clinical Biostatistics, Montpellier, France
2009 The healthy user effect in pharmacoepidemiology (invited keynote speaker for
June 2nd, 2016
19
the annual meeting of the Danish Epidemiologic Society), Denmark.
2009 Instrumental variables in pharmacoepidemiology, Research Unit in General Practice, Institute of Public Health, University of Southern Denmark.
2008 Workshop on Use of Instrumental Variable Methods, International Society of Pharmacoepidemiology, Copenhagen, Denmark.
2006 Risk of GI complications among elderly users of COX-2 inhibitors versus non-selective NSAIDs: an instrumental variable study, Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver.
MAJOR TEACHING RESPONSIBILITIES AT UNC-CHAPEL Hill
2015, 2016 Lead instructor (w/ Stephen Cole), Advanced Methods in Epidemiology (Epid 722), 1 semester course, 3 hrs/week, 33 students
2014 Instructor, Advanced Methods in Pharmacoepidemiology (Epid 799A), 1 semester course, 3 hrs/week, 13 students + 4 auditors
2013 Co-Instructor, Vaccine Epidemiology and Methods (Epid 799A), 1 semester course, 1.5 hrs/week, 14 students
2013 Lead Instructor, Epidemiologic Research with Healthcare Databases,
Department of Epidemiology (Epid 699), 1 semester course, 3 hrs/week, 21 students + 3 auditors
2013 Co-Instructor, Introduction to Pharmacoepidemiology (Epid 765), 1 semester course, 3 hrs/week, 25 students
2012 Lead Instructor, Advanced Methods in Pharmacoepidemiology (Epid 699), 1 semester course, 3 hrs/week, 21 students + 4 auditors
2011 Lead Instructor, Epidemiologic Research with Healthcare Databases,
Department of Epidemiology (Epid 699), 1 semester course, 3 hrs/week, 19 students + 5 auditors
2011 Co-Instructor, Introduction to Pharmacoepidemiology (Epid 765), 1 semester course, 3 hrs/week, 25 students
OTHER TEACHING
2015 Lead Instructor, Introduction to Pharmacoepidemiology, School of
Pharmacy, Monash University, Melbourne, Australia (8 hours, 40 students)
2014 Lead Instructor, Introduction to Pharmacoepidemiology, University of Otego, Dundein, New Zealand (8 hours, 40 students)
2013 Instructor, Annual Research Intensive, Oregon Health Sciences
June 2nd, 2016
20
University, Portland, OR (3 hours, 30 students)
2012 Lead Instructor, Introduction to Methods in Pharmacoepidemiology, Population Health Congress, Adelaide, Australia (8 hours, 40 students)
2012 Lead Instructor, Introduction to Pharmacoepidemiology, University of
Ulm Summer School in Epidemiology, Ulm Germany (4 hours/day, 25 students)
2012 Instructor, Annual Research Intensive, Oregon Health Sciences University, Portland, OR (3 hours, 30 students)
2011 Lead Instructor, Epidemiologic Analysis of Health Care Databases,
Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC (1 semester course, 3 hrs/week, 25 students)
2011 Instructor, Annual Research Intensive, Oregon Health Sciences University, Portland, OR (3 hours, 30 students)
2010 Guest Lecturer, Comparative Effectiveness Research Seminar,
Department of Health Care Policy, UNC Chapel Hill, Chapel Hill, NC (2 1 hour lectures, 30 students)
2010 Workshop organizer and instructor, Agency for Health Care Research
and Quality, Rockville, MD Designed and led a 1-day workshop on cluster randomized trials.
2009 Instructor, Merck, Designed a 1-day course on marginal structural models and propensity scores methods.
2009 Workshop organizer and instructor, Faculty of Social Work, University of
Toronto, Toronto, CA Designed and led a 1-day workshop on instrumental variable methods
2009 Instructor, Sectional on Clinical Sciences, Brigham and Women’s
Hospital Taught in a 1-week summer course on rheumatic disease epidemiology
2008 Workshop organizer and instructor, International Society of Pharmacoepidemiology Organized a workshop at the 24th Annual International Conference in Pharmacoepidemiology in Copenhagen reviewing the use of instrumental variable methods in pharmacoepidemiology.
2008 Co-organizer and presenter, International Society of Pharmacoepidemiology. Organized a symposium at the 24th Annual International Conference in Pharmacoepidemiology in Copenhagen on detecting and controlling for the healthy user effect.
2008 Workshop organizer and instructor, Agency for Health Care Research and Quality, Rockville, MD Designed and led a 2 day workshop introducing study designs and statistical methods for comparative effectiveness research.
June 2nd, 2016
21
2007 Instructor, International Society of Pharmacoepidemiology Taught a course in the educational pre-conference session at the 23rd Annual International Conference in Pharmacoepidemiology in Quebec City on the use of instrumental variable methods in pharmacoepidemiology.
2007 Workshop organizer and instructor, American College of Epidemiology
Designed and led a 1/2 day workshop on instrumental variables methods for epidemiologists.
2006 Workshop organizer and instructor, Amgen, Inc. Created and taught a 1-day short-course on statistical methods to control confounding by indication in observational studies of therapeutics.
2006 Co-organizer and presenter, International Society of Pharmacoepidemiology Co-organized a symposium at the 22nd Annual Conference of the International Society of Pharmacoepidemiology in Lisbon on statistical methods to control unmeasured confounding.
2004-2008 Guest lecturer, Department of Epidemiology, School of Public Health, Harvard School of Public Health. Contributing lecturer in course in advanced methods in pharmacoepidemiology. Lead instructor: Sebastian Schneeweiss.
2003 Instructor, School of Public Health, University of California, Berkeley
Designed and taught a course in causal inference for graduate students in public health.
1996 Graduate Student Instructor, School of Public Health, University of California at Berkeley Taught two sections of a second semester introductory biostatistics course to 20-30 public health graduate students. Held office hours and graded exams and homework.
1995-1996 Graduate Student Instructor, School of Public Health, University of California at Berkeley Taught two sections of an introductory biostatistics course to 20-30 public health graduate students. Held office hours and graded exams and homework.
Advisory and Supervisory Responsibilities
Primary Advisor for Ph.D. and Masters Degree
2014-present Ph.D. dissertation advisor for Magdalene Assimon Title: Comparative Effectiveness of Beta Antagonists in ESRD Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC Anticipated graduation date: Spring 2017
2014-present Ph.D. dissertation advisor for Sapna Rao
Title: Management of Afib in ESRD Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
June 2nd, 2016
22
Anticipated graduation date: Fall 2017 2014-present Ph.D. dissertation advisor for Marissa Seamans
Title: Within-household Patterns of Use of Opioids Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC Anticipated graduation date: Spring 2017
2012-2014 Ph.D. dissertation advisor for Anne Butler
Title: Cancer incidence in end-stage renal disease Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC Graduation date: 5/1/2014
2012-2014 Ph.D. dissertation advisor for Jane Der
Title: Evaluation of Instrumental Variable Methods for Studies of Osteoporosis Medication Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC Anticipated graduation date: 10/1/2016
2013-2014 DrPH dissertation committee co-chair for Natnaree Aimyong
Title: Inverse-probability of treatment weighted methods for competing risks data. Department of Biostatistics, UNC Chapel Hill, Chapel Hill, NC Graduation date: 8/2014
2011-present M.S., Ph.D. dissertation advisor for Xiaojuan Li,
Title: TBD Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC Anticipated graduation date: Spring 2016
2010-2012 Ph.D. dissertation advisor for Catherine Panozzo
Title: Rotavirus vaccine epidemiology Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC (Currently Instructor of Medicine, Harvard Medial School, and Harvard Pilgrim) Graduation date: 2/15/2013
2010-2015 Ph.D. dissertation advisor for Mona Cai
Title: Trends in treatment for children with Type II Diabetes Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC Anticipated graduation date: Summer 2015
2010-present M.S., Ph.D. academic advisor for Montika Bush
Title: Use and effectiveness of cardiovascular rehabilitation services in post-AMI patients Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC Anticipated graduation date: Summer 2015
2010-2012 Ph.D. dissertation advisor for Leah S. McGrath
Title: The effectiveness of the influenza vaccine in hemodialysis patients Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC (Currently, Senior Epidemiologist, Research Triangle Institute, NC) Graduation date: 12/2012
2010-2013 Ph.D. dissertation advisor for Anne Beaubrun,
Title: Patterns of Use and Outcomes of Vitamin D Treatment in
June 2nd, 2016
23
Hemodialysis Patients Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, UNC Chapel Hill, Chapel Hill, NC (Currently, Epidemiologist, Amgen, Thousand Oaks, CA) Graduation date: 12/2012
2010-2011 MPH thesis advisor for Nadiesda Costa, MD, MPH
Title: Erythropoeitin responsiveness and post-transplant outcomes Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC. (Currently renal transplant physician at UNC.) Graduation date: 5/2011
2010-2012 Ph.D. dissertation advisor for Bradley Layton
Title: Acute kidney injury among statin users Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC (Currently: Research Assistant Professor at Department of Epidemiology, UNC Chapel Hill) Graduation date 12/2012
2006-2009 Ph.D. dissertation advisor for Margaret Stedman, M.A
Title: Statistical methods for physician-randomized quality improvement interventions Department of Biostatistics, Boston University (Currently, biostatistician at NCI.) Graduation date: 12/2008
Masters or Ph.D. Thesis Committee Member
2013-2015 Ph.D. dissertation committee member for Julie Lauffenberger, Division of
Pharmaceutical Outcomes and Policy, School of Pharmacy, UNC Chapel Hill, Chapel Hill, NC
2013-2015 Ph.D. dissertation committee member for Jonathan Todd, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2013-2014 DrPH dissertation committee member for Natnaree Aimyong, Department of Biostatistics, UNC Chapel Hill, Chapel Hill, NC
2013-2014 Ph.D. dissertation committee member for Byeong Choi, Department of Biostatistics, UNC Chapel Hill, Chapel Hill, NC
2013-2015 Ph.D. dissertation committee member for Amy Richardson, Department of Biostatistics, UNC Chapel Hill, Chapel Hill, NC
2012-2014 Ph.D. dissertation committee member for Hyun Noorie, Department of Biostatistics, UNC Chapel Hill, Chapel Hill, NC
2013-present Ph.D. dissertation committee member for Levi Nord, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2011-2013 Ph.D. dissertation committee member for Heidi Soeters, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2011-2013 Ph.D. dissertation committee member for Cassidy Henegar, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
June 2nd, 2016
24
2011-2012 Ph.D. dissertation committee member for Ashley Schoenfisch, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2011-2012 Ph.D. dissertation committee member for Stephanie Watkins, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2010-2012 Ph.D. dissertation committee member for Wendy Camelo, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2010-2012 Ph.D. dissertation committee member for Emily Brouwer, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2009-2011 Ph.D. dissertation committee member for Jennifer Lund, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2010-2013 Ph.D. dissertation committee member for M. Ahinee Amamoo, Department of Epidemiology, UNC Chapel Hill, Chapel Hill, NC
2008-2009 Ph.D. committee member for Jennifer Polinski, Department of Epidemiology, HSPH, Boston, MA
2008-2009 Ph.D. committee member for Krista Huybrechts, Department of Epidemiology, Boston University, Boston, MA
2008-2012 Ph.D. committee member for Anat Fisher, Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC
2006-2008 Ph.D. committee member for Jeremy Rassen, Sc.D., Department of
Epidemiology, HSPH (Currently, Assistant Professor, Harvard Medical School).
Mentor or co-mentor for post-doctoral research fellowship
2014- Post-doctoral research fellow mentor, Anne Butler, Ph.D., Department of Epidemiology, UNC Chapel Hill
2012-2014 Post-doctoral research fellow mentor, Bradley Layton, Ph.D., Department of Epidemiology, UNC Chapel Hill
2007-2009 Post-doctoral research fellow co-mentor, Seema Parikh, MD, Brigham and Women’s Hospital, Boston, MA
2007-2008 Post-doctoral research fellow co-mentor, Suzanne Cadarette, Ph.D., University of Toronto
2007 Research Fellow co-mentor, Boris van Wijk, PharmD, Ph.D., University of Utrecht
2006 Research Fellow co-mentor, Nicola Goodman, MD, (Currently, Physician, School of Clinical Sciences, University of Liverpool.)
GRANT/CONTRACT SUPPORT
June 2nd, 2016
25
Active
2015-2017 Co-investigator, NIH 1R21AI115205-01 Effectiveness and Safety of TDAP Immunization in Pregnancy. ($417,597 total)
2014-2015 P.I., NIH NICHD, R21NR013969-01, Patterns of use, comparative
effectiveness, and safety of rotavirus vaccines. (Priority score = 10) ($417,597 total).
2014-2018 Co-investigator, NIH R01AG046267 National Literacy Mapping to Inform Healthcare Policy
2013-2015 Co-investigator, NIH 5R21AG043668 Should the Elderly Have a Lower Dose of ACE Inhibitors for Prevention after AMI?
2012-2015 P.I., NIA R01AG042845-01, A retrospective cohort study of the safety of testosterone therapy in older men ($456,000 total).
2012-2014 Co-investigator, R01 NIDDK, Comparative Effectiveness and Safety of
Newer Agents for Anemia Treatment in HD. (PI on sub-contract from Stanford to UNC, $156,854 total)
2012-2015 Co-investigator, NIA R01 AG023178-01, Use propensity score methods to assess treatment effects in the elderly
2012-2016 P.I., Amgen, Bone therapeutic area ($750,000 total): Patterns of use of
osteoporosis medications and development of machine learning methods for estimation of fracture risk.
2014-2016 P.I., Amgen, Oncology therapeutic area ($237,863 total): Initiation and adherence to bone resorption agents in metastatic prostate cancer.
2010-2016
P.I., Amgen, Nephrology therapeutic area ($1,250,000 total): Patterns of use of Cinacalcet and anemia medications; and application of methods to study dynamic treatment regimens.
2014-2016 Co-PI, R01HL118255 (PI Jonsson Funk) Methods for estimating sex differences in safety and effectiveness of drugs.
Pending
2016-2018 P.I., NIDA NIH R21, Patterns of use of opioids analgesic within households.
2016-2020 P.I., NIH R01PA-10-006, Epidemiology of pain and safety of analgesics in U.S. Hemodialysis Patients.
2016-2019 Co-PI, NIH R01 AG023178 (PI Sturmer), Propensity Scores and Preventive Drug Use in the Elderly.
Completed
2012-2014 Co-investigator, PCORI, Methods to increase validity of comparative effectiveness research in the elderly ($690,502 total).
2012-2014 P.I., AHRQ HHSA29020100014, Developing and evaluating methods for record linkage and reducing bias in patient registries ($1,112,042 total).
2012-2014 P.I., Amgen, Methodological Issues in Drug Utilization Research. ($269,960 total)
2010-2013 P.I., AHRQ DEcIDE Program ARRA-CER contract, Comparative Effectiveness of Intravenous Iron in ESRD. ($2,836,647 total)
2008-2012 Co-investigator, N.I.H., P60 AR047782, Improving Medication
Adherence for Osteoporosis: Community Based Randomized Controlled Trial. ($799,726 direct)
2011-2012 P.I., AHRQ, Inverse-probability of missing data-weighted estimators to
account for missing lab values in pharmacoepidemiologic studies. ($125,000 total)
June 2nd, 2016
26
2009-2011 Co-investigator, CVS Caremark, Adherence to Recommended Treatments—A Program of Interdisciplinary Research. ($3,000,000 total)
2006-2011 P.I., NIH, K25AG027400, Hierarchical Models of Prescription Drug Use in the Elderly. ($653,949 direct)
2006-2011 Consultant, NIH/US EPA, R01 ES013519, Indicators of Recreational Water Contamination and Illness. ($2,138,632 total)
2009-2010 P.I., Harvard Catalyst, The Effect of Exposure to Ambient Particulate
Matter on Clinical Outcomes and EPO Response in ESRD. ($50,000 direct)
2008-2009 P.I., Amgen, Hypoxia, Erythropoietin Dosing, and Outcomes. ($180,000 total)
2006-2009 P.I., Research Triangle Institute, Utilization and Outcomes of
Recombinant Human Erythropoietin in Hemodialysis Patients ($330,940 total)
2005-2009 Co-investigator, American Heart Association, Kidney Function and Use of Preventive Medications after Myocardial Infarction. ($236,636 direct)
2006-2007 P.I. (Agency for Healthcare Research and Quality, DEcIDE program,
290-2005-0016- I-TO3-WA1) Instrumental variable methods for comparative safety and effectiveness research ($249,000 total).
2006-2007 P.I., Amgen, Evaluation of Outcomes of Vascular Access Procedures. ($38,200 total)
2005-2007 Co-investigator, Satellite Healthcare, Inc., Secondary Prevention After
Myocardial Infarction - Temporal Trends and the Role of Chronic Kidney Disease. ($100,820 direct)
2003-2006 Co-investigator, N.I.H., RO1 AG21950-01, Effects of Income-based Drug Charges in Older Patients. ($761,299 direct)
2003-2006 Co-investigator, N.I.H., RO1 MH069772, Reimbursement Limits, Antidepressants, and Outcomes. ($774,580 direct)
PROFESSIONAL SERVICE
University and Department
2015-present Member, Faculty Advisory Committee, Renaissance Computing Institute, Chapel Hill, NC
2014-2015 Member, NC TRACS CER Strategic Planning Committee
2014 Member, Search Committee for Director of Cecil G. Sheps Center for Health Services Research
2013 Member, Sheps Center Review Committee
2012-2013 Member, Curriculum Review Subcommittee, Department of Epidemiology, UNC Chapel Hill
2011 Member, Planning committee for 6th Annual Drug Conference, UNC School of Pharmacy
2011 Reviewer, NCTracs small grant study section
2010 Member, Kark Teaching Assistant Award Committee, Department of Epidemiology, UNC Chapel Hill
2010-present Member, Carolina Data Warehouse Steering Committee
2010-present Member, Graduate Studies Committee, Department of Epidemiology, UNC Chapel Hill
Editorial Responsibilities
June 2nd, 2016
27
2014- Honorary Editorial Board Member, Clinical Epidemiology
2014- Editorial Board Member, Observational Studies
2010-2016 Statistical Editor, Circulation: Cardiovascular Quality and Outcomes
2008- Editorial Board Member, Pharmacoepidemiology and Drug Safety
2014- Editorial Board Member, Observational Studies
2016 Editorial Board Member, American Journal of Kidney Disease
Invited Reviewer
2008- JAMA 2008- American Journal of Kidney Disease 2008- Kidney International 2008 Biometrics 2007- Circulation 2007- Statistical Applications in Genetics and Molecular Biology 2007- British Medical Journal 2007 Medical Decision Making 2007 BMC Gastroenterology 2007 New England Journal of Medicine 2007 American Journal of Managed Care 2007 International Journal of Biostatistics 2006- Epidemiology 2006 European Journal of Clinical Pharmacology 2006 Medscape General Medicine eJournal 2005-2006 Archives of Internal Medicine 2004-2008 Pharmacoepidemiology and Drug Safety 2004-2008 Statistics in Medicine 2004-2007 Journal of Clinical Epidemiology 2004- American Journal of Epidemiology 2002 Social Service Review
Abstract Reviewer
2006- Annual Meeting of the International Society of Pharmacoepidemiology and Drug Safety
Other Professional/Service Roles
2016 Grant Reviewer, Medical Research Council, United Kingdom
2015- Independent Statistical Advisor and Member of the
External Advisory Committee, Vaccines and Medications in Pregnancy Surveillance System
2015-present Member, National Heart Lung and Blood Institute
Mentored Patient-Oriented Research Review Committee, MPOR (JA)
2015-present Member, US Renal Data Systems Expert Advisory
Panel, National Institute of Diabetes and Digestive and Kidney Diseases
June 2nd, 2016
28
2015-present Ad hoc grant review, Patient Centered Outcomes Research Institute
2014 Grant reviewer, Netherlands Organisation for Scientific Research
2013 Grant Reviewer, Tryg Foundation, Coppenhagen, Denmark
2013 Grant Reviewer, PhRMA Foundation Young Investigator award.
2012 Member, Ad Hoc Grant Review Committee, National Institute on Aging, National Institute of Health
2011 Grant Reviewer, Health Technology Assessment (HTA) methodology Programme, Netherlands Organisation for Health Research and Development (ZonMw), Netherlands
2011 Member, Agency for Healthcare Research and
Quality, 2011 Methods Conference Planning Committee
2011 Outside dissertation reader, McGill University
2011 Outside reader for Ph.D. thesis of Raluca Ionescu, Department of Epidemiology, McGill University
2010 Member, Mock Cardiorenal Advisory Committee meeting, Amgen (honorarium paid to institution)
2010 Member, Comparative Effectiveness Research Taskforce, American Society of Nephrology.
2009- Member, Confounding by Indication II Research Group. A second research advisory group organized by Research Triangle Institute to propose approaches to combat confounding in studies of bone resorption agents.
2009 Reviewer, Harvard Catalyst CTSA Pilot Grant Program
2009 Chair, Methods Incubator Working Group, Division of Pharmacoepidemiology, Brigham and Women’s Hospital. A research group that meets bi-weekly to discuss and develop new methodology for Pharmacoepidemiology.
2009 Member, Denosumab Large Simple Trial Advisory Board, Amgen
2009- Member, Data Safety Monitoring Board of the VA
Keratinocyte Chemoprevention Trial, Boston Cooperative Studies Program Coordinating Center.
2008 Member, Pharmacoeconomic Advisory Panel, Amgen
2006-2009 Member, Confounding by Indication Research Group. A research advisory group organized by Research Triangle Institute to propose approaches to combat confounding in studies of anemia management.
Professional Societies
2007- American College of Epidemiology, Member 2010- American Society of Nephrology, Member 2005- American Statistical Association, Member 2005-2008 American Geriatrics Society, Member 2003- International Society for Pharmacoepidemiology, Member
June 2nd, 2016
29
2000-2005 Institute of Mathematical Statistics, Member
